drugset

drugset / Trial / NCT05029960

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

NCT05029960 ↗

Phase 0 Terminated 3 enrolled University of Rochester

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.

Timeline

Start: 2022-05-17
Primary completion: 2024-05-09
Completion: 2024-05-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brivaracetam	Small molecule	50 mg	—

Indications